Could a Low-Dose antipsychotic ease long COVID brain fog?
NCT ID NCT07714213
First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time
Summary
This study tests whether a low dose of aripiprazole, a drug used for psychiatric conditions, can reduce fatigue and improve thinking in adults with Long COVID or other post-infection syndromes. About 138 participants will receive either the drug or a placebo for 8 weeks, then switch to the other treatment. The goal is to see if it safely eases symptoms like brain fog and low energy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- low-dose aripiprazole (1 mg)
- What this could lead to
- If it works, this could point toward a treatment for fatigue and cognitive problems in people with Long COVID and similar post-infection syndromes.
- What could go wrong
- This is an early-phase trial with only 138 participants, so results may not apply to everyone. Aripiprazole can cause side effects like drowsiness or restlessness, and the low dose may not be effective.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST-ACUTE INFECTIOUS SYNDROME (PAIS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Charité - Universitätsmedizin Berlin
Berlin, State of Berlin, 10117, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.